Atezolizumab Shows First-Line Potential For Advanced Nonsquamous NSCLC Brain Metastases
From the 2021 World Conference on Lung Cancer:
Combining first-line chemotherapy with atezolizumab could improve outcomes for patients with nonsquamous non-small-cell lung cancer and asymptomatic brain metastases
POSEIDON Immunotherapy Plus Chemotherapy Approach Improves Metastatic NSCLC Survival
From the 2021 World Conference on Lung Cancer:
Durvalumab given with or without tremelimumab may improve the outcomes of patients undergoing first-line treatment for metastatic non-small-cell lung cancer
Total Abdominal Hysterectomy May Boost Survival For Uterine Cancer With Distant Organ Metastases
Receipt of total abdominal hysterectomy with chemotherapy may improve survival compared with chemotherapy alone in women with uterine cancer whose disease has spread to distant organs
No Benefit From Adding Ipilimumab To Second-Line Nivolumab For Advanced Squamous NSCL
Adding ipilimumab to nivolumab does not extend overall survival for stage IV squamous non-small-cell lung cancer patients who have progressed after chemotherapy
Liquid Biopsy-Directed Treatment Improves Advanced NSCLC Overall Survival
Advanced NSCLC patients who receive targeted treatment based on circulating tumour or tissue-detected DNA alterations have better overall survival than those who do not